Compare Ascendis Pharma A/S (ASND) vs Lennar Corporation (LEN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Lennar Corporation — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Lennar Corporation trades at $84.5 (market cap $20.25B). The key difference: Ascendis Pharma A/S and Lennar Corporation are close in size by market cap, and Lennar Corporation pays a 2.37% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | LEN | |
|---|---|---|
Market Cap | $17.74B | $20.25B |
Sector | Health | Consumer Cyclical |
52-Week High | $277.18 | $142.40 |
52-Week Low | $163.32 | $82.30 |
Enterprise Value | $18.11B | $24.13B |
Dividend Yield | — | 2.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Lennar Corporation (LEN) trades at $84.27, down 0.09% on the day, with the stock showing bearish technical signals despite trading near analyst consensus targets. The homebuilder faces margin pressure with net income declining from $4.6B in 2022 to $2.1B in 2025, though valuation metrics appear attractive with P/E of 13.2 and P/B of 0.9. Recent earnings have consistently missed expectations, with Q2 2026 results showing mixed performance amid challenging housing market conditions.
LEN presents a value opportunity with discounted valuations but faces significant headwinds from declining profitability and housing market volatility. The stock's outlook hinges on execution amid affordability pressures, with analyst consensus leaning bullish (46% buy ratings) but technical indicators suggesting caution. Key risks include ongoing margin compression and macroeconomic sensitivity to interest rates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Lennar Corporation
Lennar is the second-largest public homebuilder in the United States. The company's homebuilding operations target first-time, move-up, and active adult homebuyers mainly under the Lennar brand name. Lennar's financial-services segment provides mortgage financing and related services to its homebuyers. Miami-based Lennar is also involved in multifamily construction and has invested in numerous housing-related technology startups.
Read more on LEN →
